DHR vs PFE: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
Danaher Corporation · Healthcare
$221.12
+29.6% upside to fair value
Med Conviction
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
DHR has more upside to fair value
(+29.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
PFE |
| Current Price |
$221.12 |
$27.64 |
| Fair Value Estimate |
$286.52 |
$30.94 |
| Upside to Fair Value |
+29.6%
|
+12.0%
|
| Market Cap |
$155.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
17.4x
|
| Price / Sales |
6.2x
|
2.5x
|
| Price / FCF |
28.5x
|
14.3x
|
| Revenue Growth YoY |
+5.5%
|
+2.6%
|
| Gross Margin |
58.5%
|
71.3%
|
| Operating Margin |
20.4%
|
25.1%
|
| Return on Equity |
7.7%
|
4.9%
|
| Dividend Yield |
0.65% |
6.22% |
| FCF Yield |
3.51%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher is a diversified life-sciences and diagnostics platform spanning three segments: Life Sciences (mass spectrometers, flow cytometry, genomics, bioprocess technologies), Diagnostics (chemistry, immunoassay, microbiology, hematology, molecular and pathology systems), and Environmental & Applied Solutions (water quality and product-identification instrumentation). The business quality is high…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
DHR |
PFE |
| Zone Low |
$214.89 |
$23.21 |
| Zone High |
$243.54 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|